Avenacy launches 2 new generics
Avenacy, a specialty pharmaceutical company focused on supplying injectable medications, has launched Fosaprepitant for Injection and Fulvestrant Injection.
“Avenacy has had a strong start to 2024, with two product launches already executed and two more newly announced additions to our rapidly expanding portfolio. Since the company’s launch in October, we have invested in bringing high-demand injectable products to market and strengthening our global network of development and manufacturing partners, and we are ready to build upon this important foundation as we prepare for significant growth,” said Jeff Yordon, co-founder and CEO of Avenacy.
Yordon added, “We are looking forward to participating in DCAT 2024, where we will be discussing how Avenacy is well-positioned to continue addressing key gaps in the U.S. drug supply landscape through its differentiated portfolio, robust pipeline, and unwavering commitment to quality, safety, and patient care.”
Fosaprepitant for Injection is a generic of Merck & Co.’s Emend.
[Read more: Generic sterile injectables market to reach $196.2B by 2029]
Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin; delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
Fosaprepitant for Injection had a market value of approximately $35 million for the 12 months ending in June 2023, per IQVIA.
Avenacy’s product contains 150 mg of Fosaprepitant as a lyophilized powder in a single-dose vial for reconstitution.
Fulvestrant Injection is a generic of AstraZeneca’s Faslodex.
[Read more: AAM report: Generics, biosimilars generated $373B savings in 2021]
It is indicated for: monotherapy use for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy; or HR positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy; combination therapy use for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy; or HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
Fulvestrant Injection had a market value of approximately $71 million for the 12 months ending in June 2023, per IQVIA.
Avenacy’s product is supplied as 5 ml pre-filled syringes for injection containing 250 mg per 5 ml Fulvestrant.